Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab in relapsed or refractory follicular or marginal zone lymphoma
jRCT2061250006Phase 3Active, not recruiting
- Sponsor
- BeOne Medicines
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of zanubrutinib, obinutuzumab, lenalidomide and rituximab in follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) (2 arms), sponsored by BeOne Medicines. Primary endpoint: Progression-free survival. Started Jun 2025; status: active, not recruiting.
02
Drugs
zanubrutinibobinutuzumablenalidomiderituximab
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on jRCT2061250006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250006.